MedTrace Logo

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

NCT02317471 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-06-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of autologous gp96 treatment of gastric cancer.

Conditions

  • Gastric Carcinoma

Interventions

BIOLOGICAL

autologous gp96 vaccination

Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery. gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion.

DRUG

Oxaliplatin+S-1

Treatment will be start at the 5th week after the surgery. S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles.

Sponsors & Collaborators

  • Cure&Sure Biotech Co., LTD

    collaborator INDUSTRY

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Lin Chen, MD · Chinese PLA General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02317471 on ClinicalTrials.gov